Omnicell, Inc. (NASDAQ:OMCL) Stake Boosted by Diversified Trust Co

Diversified Trust Co increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 43.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,966 shares of the company’s stock after acquiring an additional 6,602 shares during the period. Diversified Trust Co’s holdings in Omnicell were worth $958,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in OMCL. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares during the period. EntryPoint Capital LLC boosted its position in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after acquiring an additional 1,345 shares during the period. CWM LLC grew its position in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its holdings in shares of Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after acquiring an additional 868 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on OMCL. JPMorgan Chase & Co. boosted their price target on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Bank of America upped their price target on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company lifted their price objective on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Finally, Benchmark reaffirmed a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $37.83.

Omnicell Stock Up 1.9 %

OMCL opened at $43.04 on Wednesday. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $46.05. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -93.57, a PEG ratio of 46.63 and a beta of 0.83. The firm’s 50-day simple moving average is $42.36 and its 200-day simple moving average is $33.45. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 0.64 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.